Natus scales back Q2 revenue projections; GeneCentric raises $2.5M for cancer Dx development;

 @FierceMedDev: Roche chases FDA cancer indication for HPV diagnostic. Story | Follow @FierceMedDev

 @MarkHFierce: Duke has found early promise with a blood Dx that predicts aspirin treatment success. Report | Follow @MarkHFierce

 @DamianFierce: Patient lawsuits mount as India tries to crack down on unethical clinical trials. Item | Follow @DamianFierce

> Natus Medical ($BABY) has scaled back its second-quarter revenue projections by about 9%, expecting up to $82 million thanks to weak international sales. Release

> Terumo has started selling BSD Medical's ($BSDM) MicroThermX ablation system in Europe, following a licensing deal the two struck in the spring. News

> Diagnostics outfit GeneCentric has raised $2.5 million to develop cancer tests. Article

> Life Care Medical Devices has signed up with M.E.D. Surgical to distribute its Keyhole Cup laparoscopic access device in Ireland. Item

> Game developers are designing programs designed to treat mental disorders like depression and anxiety, but none has been approved by the FDA. Story

> Startup HeadSense has secured an undisclosed amount of financing to develop its non-invasive brain monitor for intracranial pressure. More

> Johns Hopkins physicians successfully used an endoscopy procedure to place a small metal stent in the stomach to treat patients who suffer from gastroparesis-related health problems. Item

> BD ($BDX) named Christopher Reidy as its new chief financial officer, a veteran ADP executive who also held similar roles at AT&T and Deloitte & Touche. Release

Biotech News

 @FierceBiotech: SEC hunting down traders who made a quick killing on Onyx shares. Report | Follow @FierceBiotech

 @JohnCFierce: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown. News | Follow @JohnCFierce

 @RyanMFierce: For those of you who remember Son of Lantus, watch out for Lantus' fraternal (not identical) twin from Lilly and Boehringer. | Follow @RyanMFierce

 @EmilyMFierce: Cholera is altering the human genome. Story | Follow @EmilyMFierce

> Swiss biotech OncoEthix snags $19M round to back leukemia drug study. More

> Cytokinetics shares slide on dosing snafu in ALS drug study. Article

> Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown. Story

Pharma News

 @FiercePharma: Cost watchdogs veto Novartis breast cancer med Afinitor. NICE says "disappointed" data isn't stronger. News | Follow @FiercePharma

> Roche bids for broad use of HPV test to screen for cervical cancer. Story

> Lilly's Lechleiter returns to CEO suite after surgery. More

> Vivus, FMC both tout proxy advisers' support for board nominees. Article

> Medicare won't pay for Eli Lilly Alzheimer's agent. News

CRO News

> Report: Academia could better use CROs for early research. News

> Lawsuits mount as India pushes trial reforms. Article

> CRO Blue Sky taps new CEO amid growth. Story

> Parexel teams with Rutgers for clinical trials. More

> CROs shift as early-phase demand dries up. News

Biotech IT News

> Report: Pharma execs warm to med reminder apps. News

> GE, Accenture back analytics provider in $20M financing. Article

> Bioinformatics gives U. Wisconsin team an 'edge' in cystic fibrosis study. Story

> AstraZeneca snaps up drug-discovery software from Cambridge startup. More

> Facebook, Twitter bolster Canadian biotech's research of Crohn's therapy. News

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.